{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:55:20Z","timestamp":1791212120642,"version":"4.1.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,22]],"date-time":"2024-09-22T00:00:00Z","timestamp":1726963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,22]],"date-time":"2024-09-22T00:00:00Z","timestamp":1726963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Zhejiang Provincial Natural Science Foundation of China under","award":["LY19H160010"],"award-info":[{"award-number":["LY19H160010"]}]},{"name":"Zhejiang Provincial Natural Science Foundation of China under","award":["LY19H160011"],"award-info":[{"award-number":["LY19H160011"]}]},{"name":"Zhejiang Provincial Natural Science Foundation of China under","award":["LQ22H160008"],"award-info":[{"award-number":["LQ22H160008"]}]},{"name":"Zhejiang Medicine and Health Science and Technology Project","award":["2018KY702"],"award-info":[{"award-number":["2018KY702"]}]},{"DOI":"10.13039\/100007834","name":"Natural Science Foundation of Ningbo","doi-asserted-by":"crossref","award":["2021J314"],"award-info":[{"award-number":["2021J314"]}],"id":[{"id":"10.13039\/100007834","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Open-end Fund of Key Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang Province","award":["KFJJ-202002"],"award-info":[{"award-number":["KFJJ-202002"]}]},{"name":"HwaMei Key Research Foundation of Ningbo No.2 Hospital","award":["2024HMZD02"],"award-info":[{"award-number":["2024HMZD02"]}]},{"name":"Huawei Research Foundation of Ningbo No.2 Hospital","award":["2023HMKY44"],"award-info":[{"award-number":["2023HMKY44"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Colorectal cancer (CRC) is the second common cause of cancer mortality worldwide, and it still lacks effective approaches for relapsed and metastatic CRC. Recently, oncolytic virus has been emerged as a promising immune therapeutic strategy. In this study, we develop a novel oncolytic adenovirus, rAd.mDCN.mCD40L, which drive oncolytic activity by telomerase reverse transcriptase promoter (TERTp). rAd.mDCN.mCD40L expressed both mouse genes of decorin (mDCN) and CD40 ligand (mCD40L), and produced effective cytotoxicity in both human and mouse CRC cells. Moreover, oncolytic adenovirus mediated mDCN over-expression inhibited Met expression in vitro. In CT26 subcutaneous tumor model, intratumorally delivery of oncolytic adenoviruses could inhibit tumor growth and liver metastasis, while mDCN and\/or mCD40L armed oncolytic adenoviruses produced much more impressive responses. No obvious toxicity was detected in lung, liver and spleen. Moreover, mDCN and\/or mCD40L armed oncolytic adenoviruses altered the immune state to activate anti-tumor responses, including increasing CD8<jats:sup>+<\/jats:sup> T effector cells and CD4<jats:sup>+<\/jats:sup> memory T cells, reducing MDSCs and Tregs in peripheral blood. Furthermore, mDCN and\/or mCD40L armed oncolytic adenoviruses mediated mDCN and\/or mCD40L expression in tumors, and up-regulated Th1 cytokines and reduced Th2 cytokines in tumors, which will be benefit for remodeling tumor microenvironment. Importantly, rAd.mDCN.mCD40L and rAd.mCD40L prevented tumor liver metastasis much more effectively than rAd.Null and rAd.mDCN. Therefore, rAd.mDCN.mCD40L and rAd.mCD40L are promising approaches for CRC therapy.<\/jats:p>","DOI":"10.1186\/s43556-024-00202-1","type":"journal-article","created":{"date-parts":[[2024,9,22]],"date-time":"2024-09-22T03:17:01Z","timestamp":1726975021000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Oncolytic adenovirus encoding decorin and CD40 ligand inhibits tumor growth and liver metastasis via immune activation in murine colorectal tumor model"],"prefix":"10.1186","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9423-3002","authenticated-orcid":false,"given":"Yejing","family":"Rong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjun","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiachang","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6537-2102","authenticated-orcid":false,"given":"Yuefeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,22]]},"reference":[{"issue":"7","key":"202_CR1","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1001\/jama.2021.0106","volume":"325","author":"LH Biller","year":"2021","unstructured":"Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325(7):669\u201385. https:\/\/doi.org\/10.1001\/jama.2021.0106.","journal-title":"JAMA"},{"issue":"3","key":"202_CR2","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/ajg.2016.22","volume":"111","author":"CJ Kahi","year":"2016","unstructured":"Kahi CJ, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, et al. Colonoscopy surveillance after colorectal cancer resection: recommendations of the US Multi-Society Task Force on colorectal cancer. Am J Gastroenterol. 2016;111(3):337\u201346; quiz 347. https:\/\/doi.org\/10.1038\/ajg.2016.22.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"202_CR3","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ccell.2023.01.001","volume":"41","author":"X Liu","year":"2023","unstructured":"Liu X, Song J, Zhang H, Liu X, Zuo F, Zhao Y, et al. Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance. Cancer Cell. 2023;41(2):272-e2879. https:\/\/doi.org\/10.1016\/j.ccell.2023.01.001.","journal-title":"Cancer Cell"},{"issue":"6","key":"202_CR4","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","volume":"170","author":"A Ribas","year":"2017","unstructured":"Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170(6):1109-e111910. https:\/\/doi.org\/10.1016\/j.cell.2017.08.027.","journal-title":"Cell"},{"issue":"559","key":"202_CR5","doi-asserted-by":"publisher","first-page":"eaaz1863","DOI":"10.1126\/scitranslmed.aaz1863","volume":"12","author":"AK Park","year":"2020","unstructured":"Park AK, Fong Y, Kim SI, Yang J, Murad JP, Lu J, et al. Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors. Sci Transl Med. 2020;12(559):eaaz1863.\u00a0https:\/\/doi.org\/10.1126\/scitranslmed.aaz1863.","journal-title":"Sci Transl Med"},{"issue":"11","key":"202_CR6","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1158\/1078-0432.CCR-20-1565","volume":"27","author":"M Farrera-Sal","year":"2021","unstructured":"Farrera-Sal M, Moya-Borrego L, Bazan-Peregrino M, Alemany R. Evolving status of clinical immunotherapy with oncolytic adenovirus. Clin Cancer Res. 2021;27(11):2979\u201388. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-1565.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"202_CR7","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1038\/leu.2010.191","volume":"24","author":"WG Wierda","year":"2010","unstructured":"Wierda WG, Castro JE, Aguillon R, Sampath D, Jalayer A, McMannis J, et al. A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154. Leukemia. 2010;24(11):1893\u2013900. https:\/\/doi.org\/10.1038\/leu.2010.191.","journal-title":"Leukemia"},{"issue":"6","key":"202_CR8","doi-asserted-by":"publisher","first-page":"941","DOI":"10.2217\/fon.10.66","volume":"6","author":"HL Kaufman","year":"2010","unstructured":"Kaufman HL, Bines SD. OPTIM trial: a phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol. 2010;6(6):941\u20139. https:\/\/doi.org\/10.2217\/fon.10.66.","journal-title":"Future Oncol"},{"issue":"13","key":"202_CR9","doi-asserted-by":"publisher","first-page":"4169","DOI":"10.1245\/s10434-016-5286-0","volume":"23","author":"RH Andtbacka","year":"2016","unstructured":"Andtbacka RH, Ross M, Puzanov I, Milhem M, Collichio F, Delman KA, et al. Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial. Ann Surg Oncol. 2016;23(13):4169\u201377. https:\/\/doi.org\/10.1245\/s10434-016-5286-0.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"202_CR10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1158\/2159-8290.CD-NB2015-158","volume":"6","author":"A Poh","year":"2016","unstructured":"Poh A. First oncolytic viral therapy for melanoma. Cancer Discov. 2016;6(1):6. https:\/\/doi.org\/10.1158\/2159-8290.CD-NB2015-158.","journal-title":"Cancer Discov"},{"issue":"8","key":"202_CR11","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1158\/1078-0432.CCR-21-3324","volume":"28","author":"EHP van Putten","year":"2022","unstructured":"van Putten EHP, Kleijn A, van Beusechem VW, Noske D, Lamers CHJ, de Goede AL, et al. Convection enhanced delivery of the oncolytic adenovirus Delta24-RGD in patients with recurrent GBM: a phase I clinical trial including correlative studies. Clin Cancer Res. 2022;28(8):1572\u201385. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3324.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"202_CR12","doi-asserted-by":"publisher","first-page":"e003645","DOI":"10.1136\/jitc-2021-003645","volume":"9","author":"V Moreno","year":"2021","unstructured":"Moreno V, Barretina-Ginesta MP, Garc\u00eda-Donas J, Jayson GC, Roxburgh P, V\u00e1zquez RM, et al. Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial. J Immunother Cancer. 2021;9(12):e003645.\u00a0https:\/\/doi.org\/10.1136\/jitc-2021-003645","journal-title":"J Immunother Cancer"},{"issue":"11","key":"202_CR13","doi-asserted-by":"publisher","first-page":"e003254","DOI":"10.1136\/jitc-2021-003254","volume":"9","author":"M Bazan-Peregrino","year":"2021","unstructured":"Bazan-Peregrino M, Garcia-Carbonero R, Laquente B, \u00c1lvarez R, Mato-Berciano A, Gimenez-Alejandre M, et al. VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects. J Immunother Cancer. 2021;9(11):e003254.\u00a0https:\/\/doi.org\/10.1136\/jitc-2021-003254.","journal-title":"J Immunother Cancer"},{"issue":"476","key":"202_CR14","doi-asserted-by":"publisher","first-page":"eaat9321","DOI":"10.1126\/scitranslmed.aat9321","volume":"11","author":"G Pascual-Pasto","year":"2019","unstructured":"Pascual-Pasto G, Bazan-Peregrino M, Olaciregui NG, Restrepo-Perdomo CA, Mato-Berciano A, Ottaviani D, et al. Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01. Sci Transl Med. 2019;11(476):eaat9321.\u00a0https:\/\/doi.org\/10.1126\/scitranslmed.aat9321.","journal-title":"Sci Transl Med"},{"issue":"3","key":"202_CR15","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1089\/hum.2018.107","volume":"30","author":"M Garc\u00eda","year":"2019","unstructured":"Garc\u00eda M, Moreno R, Gil-Martin M, Cascall\u00f2 M, de Olza MO, Cuadra C, et al. A phase 1 trial of oncolytic adenovirus ICOVIR-5 administered intravenously to cutaneous and uveal melanoma patients. Hum Gene Ther. 2019;30(3):352\u201364. https:\/\/doi.org\/10.1089\/hum.2018.107.","journal-title":"Hum Gene Ther"},{"issue":"3","key":"202_CR16","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/sj.cgt.7701105","volume":"15","author":"ZB Hu","year":"2008","unstructured":"Hu ZB, Wu CT, Wang H, Zhang QW, Wang L, Wang RL, et al. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes. Cancer Gene Ther. 2008;15(3):173\u201382. https:\/\/doi.org\/10.1038\/sj.cgt.7701105.","journal-title":"Cancer Gene Ther"},{"key":"202_CR17","doi-asserted-by":"publisher","unstructured":"Guise, Xiao, Morgan, Yang, Brendler, Prabhakar, et al. Ad5\/48 hexon oncolytic virus expressing sTGF\u03b2RIIFc produces reduced hepatic and systemic toxicities and inhibits prostate cancer bone metastases. Mol Ther. 2014; 22(8):1504\u20131517. https:\/\/doi.org\/10.1038\/mt.2014.80.","DOI":"10.1038\/mt.2014.80"},{"issue":"8","key":"202_CR18","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1089\/hum.2017.033","volume":"28","author":"Z Liu","year":"2017","unstructured":"Liu Z, Yang Y, Zhang X, Wang H, Xu W, Wang H, et al. An oncolytic adenovirus encoding decorin and granulocyte macrophage colony stimulating factor inhibits tumor growth in a colorectal tumor model by targeting pro-tumorigenic signals and via immune activation. Hum Gene Ther. 2017;28(8):667\u201380. https:\/\/doi.org\/10.1089\/hum.2017.033.","journal-title":"Hum Gene Ther"},{"issue":"9","key":"202_CR19","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1089\/hum.2019.059","volume":"30","author":"P Seth","year":"2019","unstructured":"Seth P, Yang Y, Xu W, Peng D, Wang L. An oncolytic adenovirus targeting TGF\u03b2 inhibits pro-tumorigenic signals and produces immune activation: a novel approach to enhance anti-PD-1 and anti-CTLA-4 therapy. Hum Gene Ther. 2019;30(9):1117\u201332. https:\/\/doi.org\/10.1089\/hum.2019.059.","journal-title":"Hum Gene Ther."},{"issue":"8","key":"202_CR20","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1089\/hum.2013.160","volume":"25","author":"D Zhu","year":"2014","unstructured":"Zhu D, Chen C, Purwanti YI, Du S, Lam DH, Wu C, et al. Induced pluripotent stem cell-derived neural stem cells transduced with baculovirus encoding CD40 ligand for immunogene therapy in mouse models of breast cancer. Hum Gene Ther. 2014;25(8):747\u201358. https:\/\/doi.org\/10.1089\/hum.2013.160.","journal-title":"Hum Gene Ther"},{"issue":"6","key":"202_CR21","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/CJI.0b013e31829d8a1b","volume":"36","author":"S Westberg","year":"2013","unstructured":"Westberg S, Sadeghi A, Svensson E, Segall T, Dimopoulou M, Korsgren O, et al. Treatment efficacy and immune stimulation by AdCD40L gene therapy of spontaneous canine malignant melanoma. J Immunotherapy. 2013;36(6):350\u20138. https:\/\/doi.org\/10.1097\/CJI.0b013e31829d8a1b. (Hagerstown, Md.: 1997).","journal-title":"J Immunotherapy"},{"issue":"3","key":"202_CR22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/CJI.0000000000000028","volume":"37","author":"L Liljenfeldt","year":"2014","unstructured":"Liljenfeldt L, Yu D, Chen L, Essand M, Mangsbo SM. A hexon and fiber-modified adenovirus expressing CD40L improves the antigen presentation capacity of dendritic cells. J Immunother. 2014;37(3):155\u201362. https:\/\/doi.org\/10.1097\/CJI.0000000000000028.","journal-title":"J Immunother"},{"issue":"10","key":"202_CR23","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1158\/1078-0432.CCR-19-2427","volume":"26","author":"RA Figlin","year":"2020","unstructured":"Figlin RA, Tannir NM, Uzzo RG, Tykodi SS, Chen DYT, Master V, et al. Results of the ADAPT phase 3 study of rocapuldencel-T in combination with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma. Clin cancer Research: Official J Am Association Cancer Res. 2020;26(10):2327\u201336. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2427.","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"issue":"7","key":"202_CR24","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1158\/0008-5472.CAN-11-3001","volume":"72","author":"S Pesonen","year":"2012","unstructured":"Pesonen S, Diaconu I, Kangasniemi L, Ranki T, Kanerva A, Pesonen SK, et al. Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients. Cancer Res. 2012;72(7):1621\u201331. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-3001.","journal-title":"Cancer Res"},{"issue":"8","key":"202_CR25","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/gt.2014.46","volume":"21","author":"YF Yang","year":"2014","unstructured":"Yang YF, Xue SY, Lu ZZ, Xiao FJ, Yin Y, Zhang QW, et al. Antitumor effects of oncolytic adenovirus armed with PSA-IZ-CD40L fusion gene against prostate cancer. Gene Ther. 2014;21(8):723\u201331. https:\/\/doi.org\/10.1038\/gt.2014.46.","journal-title":"Gene Ther"},{"issue":"12","key":"202_CR26","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1089\/hum.2015.098","volume":"26","author":"Y Yang","year":"2015","unstructured":"Yang Y, Xu W, Neill T, Hu Z, Wang CH, Xiao X, et al. Systemic delivery of an oncolytic adenovirus expressing decorin for the treatment of breast cancer bone metastases. Hum Gene Ther. 2015;26(12):813\u201325. https:\/\/doi.org\/10.1089\/hum.2015.098.","journal-title":"Hum Gene Ther"},{"issue":"3","key":"202_CR27","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/gt.2014.110","volume":"22","author":"W Xu","year":"2015","unstructured":"Xu W, Neill T, Yang Y, Hu Z, Cleveland E, Wu Y, et al. The systemic delivery of an oncolytic adenovirus expressing decorin inhibits bone metastasis in a mouse model of human prostate cancer. Gene Ther. 2015;22(3):247\u201356. https:\/\/doi.org\/10.1038\/gt.2014.110.","journal-title":"Gene Ther"},{"issue":"1","key":"202_CR28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2174\/187153007780059432","volume":"7","author":"A Loskog","year":"2007","unstructured":"Loskog A, Totterman TH. CD40L - a multipotent molecule for tumor therapy. Endocr Metab Immune Disord Drug Targets. 2007;7(1):23\u20138. https:\/\/doi.org\/10.2174\/187153007780059432.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"26","key":"202_CR29","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.2016.67.9761","volume":"34","author":"C Massard","year":"2016","unstructured":"Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncology: Official J Am Soc Clin Oncol. 2016;34(26):3119\u201325. https:\/\/doi.org\/10.1200\/JCO.2016.67.9761.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"9","key":"202_CR30","doi-asserted-by":"publisher","first-page":"djv156","DOI":"10.1093\/jnci\/djv156","volume":"107","author":"TT Chen","year":"2015","unstructured":"Chen TT. Milestone survival: a potential Intermediate endpoint for immune checkpoint inhibitors. J Natl Cancer Inst. 2015;107(9):djv156. https:\/\/doi.org\/10.1093\/jnci\/djv156.","journal-title":"J Natl Cancer Inst."},{"issue":"1","key":"202_CR31","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13045-019-0813-7","volume":"12","author":"X Han","year":"2019","unstructured":"Han X, Wang Y, Wei J, Han W. Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy. J Hematol Oncol. 2019;12(1):128. https:\/\/doi.org\/10.1186\/s13045-019-0813-7.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"202_CR32","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13045-020-00922-1","volume":"13","author":"O Hemminki","year":"2020","unstructured":"Hemminki O, Dos Santos JM, Hemminki A. Oncolytic viruses for cancer immunotherapy. J Hematol Oncol. 2020;13(1):84. https:\/\/doi.org\/10.1186\/s13045-020-00922-1.","journal-title":"J Hematol Oncol"},{"key":"202_CR33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40425-016-0121-5","volume":"4","author":"T Ranki","year":"2016","unstructured":"Ranki T, Pesonen S, Hemminki A, Partanen K, Kairemo K, Alanko T, et al. Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers. J Immunother Cancer. 2016;4:17. https:\/\/doi.org\/10.1186\/s40425-016-0121-5.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"202_CR34","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nrmicro2240","volume":"8","author":"SJ Draper","year":"2010","unstructured":"Draper SJ, Heeney JL. Viruses as vaccine vectors for infectious diseases and cancer. Nature reviews Microbiology. 2010;8(1):62\u201373. https:\/\/doi.org\/10.1038\/nrmicro2240.","journal-title":"Nature reviews. Microbiology"},{"issue":"12","key":"202_CR35","doi-asserted-by":"publisher","first-page":"e27138","DOI":"10.4161\/onci.27138","volume":"2","author":"ST Workenhe","year":"2013","unstructured":"Workenhe ST, Mossman KL. Rewiring cancer cell death to enhance oncolytic viro-immunotherapy. Oncoimmunology. 2013;2(12):e27138.\u00a0https:\/\/doi.org\/10.4161\/onci.27138.","journal-title":"Oncoimmunology"},{"issue":"4","key":"202_CR36","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1089\/hum.2013.235","volume":"25","author":"D Majhen","year":"2014","unstructured":"Majhen D, Calderon H, Chandra N, Fajardo CA, Rajan A, Alemany R, et al. Adenovirus-based vaccines for fighting infectious diseases and cancer: progress in the field. Hum Gene Ther. 2014;25(4):301\u201317. https:\/\/doi.org\/10.1089\/hum.2013.235.","journal-title":"Hum Gene Ther"},{"issue":"4","key":"202_CR37","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/nrurol.2012.19","volume":"9","author":"IJ Edwards","year":"2012","unstructured":"Edwards IJ. Proteoglycans in prostate cancer. Nature reviews Urology. 2012;9(4):196\u2013206. https:\/\/doi.org\/10.1038\/nrurol.2012.19.","journal-title":"Nature reviews Urology"},{"issue":"1","key":"202_CR38","first-page":"207","volume":"9","author":"S Troup","year":"2003","unstructured":"Troup S, Njue C, Kliewer EV, Parisien M, Roskelley C, Chakravarti S, et al. Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer. Clin cancer Research: Official J Am Association Cancer Res. 2003;9(1):207\u201314.","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"issue":"6","key":"202_CR39","first-page":"1754","volume":"8","author":"MA Nash","year":"2002","unstructured":"Nash MA, Deavers MT, Freedman RS. The expression of decorin in human ovarian tumors. Clin cancer Research: Official J Am Association Cancer Res. 2002;8(6):1754\u201360.","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"issue":"1","key":"202_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejcb.2012.08.004","volume":"92","author":"DD Sofeu Feugaing","year":"2013","unstructured":"Sofeu Feugaing DD, G\u00f6tte M, Viola M. More than matrix: the multifaceted role of decorin in cancer. Eur J Cell Biol. 2013;92(1):1\u201311. https:\/\/doi.org\/10.1016\/j.ejcb.2012.08.004.","journal-title":"Eur J Cell Biol"},{"issue":"8","key":"202_CR41","doi-asserted-by":"publisher","first-page":"314","DOI":"10.2183\/pjab.85.314","volume":"85","author":"K Miyazono","year":"2009","unstructured":"Miyazono K. Transforming growth factor-beta signaling in epithelial-mesenchymal transition and progression of cancer. Proceedings of the Japan Academy Series B, Physical and biological sciences. 2009;85(8):314\u201323. https:\/\/doi.org\/10.2183\/pjab.85.314.","journal-title":"Proceedings of the Japan Academy Series B, Physical and biological sciences"},{"issue":"1","key":"202_CR42","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/jcmm.12004","volume":"17","author":"M Mimeault","year":"2013","unstructured":"Mimeault M, Batra SK. Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells. J Cell Mol Med. 2013;17(1):30\u201354. https:\/\/doi.org\/10.1111\/jcmm.12004.","journal-title":"J Cell Mol Med"},{"issue":"2","key":"202_CR43","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3892\/or.2012.1822","volume":"28","author":"XY Ni","year":"2012","unstructured":"Ni XY, Sui HX, Liu Y, Ke SZ, Wang YN, Gao FG. TGF-beta of lung cancer microenvironment upregulates B7H1 and GITRL expression in dendritic cells and is associated with regulatory T cell generation. Oncol Rep. 2012;28(2):615\u201321. https:\/\/doi.org\/10.3892\/or.2012.1822.","journal-title":"Oncol Rep"},{"issue":"6","key":"202_CR44","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/jso.22005","volume":"104","author":"X Lu","year":"2011","unstructured":"Lu X, Liu J, Li H, Li W, Wang X, Ma J, et al. Conversion of intratumoral regulatory T cells by human gastric cancer cells is dependent on transforming growth factor-beta1. J Surg Oncol. 2011;104(6):571\u20137. https:\/\/doi.org\/10.1002\/jso.22005.","journal-title":"J Surg Oncol"},{"issue":"7693","key":"202_CR45","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544\u20138. https:\/\/doi.org\/10.1038\/nature25501.","journal-title":"Nature"},{"issue":"1","key":"202_CR46","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1093\/carcin\/bgaa092","volume":"42","author":"S Chatterjee","year":"2021","unstructured":"Chatterjee S, Chatterjee A, Jana S, Dey S, Roy H, Das MK, et al. Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer. Carcinogenesis. 2021;42(1):38\u201347. https:\/\/doi.org\/10.1093\/carcin\/bgaa092.","journal-title":"Carcinogenesis"},{"issue":"8","key":"202_CR47","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1093\/neuonc\/now009","volume":"18","author":"AA Brandes","year":"2016","unstructured":"Brandes AA, Carpentier AF, Kesari S, Sepulveda-Sanchez JM, Wheeler HR, Chinot O, et al. A phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. Neurooncology. 2016;18(8):1146\u201356. https:\/\/doi.org\/10.1093\/neuonc\/now009.","journal-title":"Neurooncology"},{"issue":"3","key":"202_CR48","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1158\/1078-0432.CCR-14-1380","volume":"21","author":"J Rodon","year":"2015","unstructured":"Rodon J, Carducci MA, Sepulveda-Sanchez JM, Azaro A, Calvo E, Seoane J, et al. First-in-human dose study of the novel transforming growth factor-beta receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma. Clin cancer Research: Official J Am Association Cancer Res. 2015;21(3):553\u201360. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-1380.","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"issue":"2","key":"202_CR49","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1089\/hum.2018.055","volume":"30","author":"H Zhao","year":"2019","unstructured":"Zhao H, Wang H, Kong F, Xu W, Wang T, Xiao F, et al. Oncolytic adenovirus rAd.DCN inhibits breast tumor growth and lung metastasis in an immune-competent orthotopic xenograft model. Hum Gene Ther. 2019;30(2):197\u2013210. https:\/\/doi.org\/10.1089\/hum.2018.055.","journal-title":"Hum Gene Ther"},{"issue":"2","key":"202_CR50","doi-asserted-by":"publisher","first-page":"e003490","DOI":"10.1136\/jitc-2021-003490","volume":"10","author":"I Liikanen","year":"2022","unstructured":"Liikanen I, Basnet S, Quixabeira DCA, Taipale K, Hemminki O, Oksanen M, et al. Oncolytic adenovirus decreases the proportion of TIM-3+ subset of tumor-infiltrating CD8+ T cells with correlation to improved survival in patients with cancer. J Immunother Cancer. 2022;10(2):e003490. https:\/\/doi.org\/10.1136\/jitc-2021-003490.","journal-title":"J Immunother Cancer"},{"key":"202_CR51","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1146\/annurev.immunol.22.012703.104533","volume":"22","author":"SA Quezada","year":"2004","unstructured":"Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ. CD40\/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol. 2004;22:307\u201328. https:\/\/doi.org\/10.1146\/annurev.immunol.22.012703.104533.","journal-title":"Annu Rev Immunol"},{"key":"202_CR52","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","volume":"71","author":"RH Vonderheide","year":"2020","unstructured":"Vonderheide RH. CD40 agonist antibodies in cancer immunotherapy. Annu Rev Med. 2020;71:47\u201358. https:\/\/doi.org\/10.1146\/annurev-med-062518-045435.","journal-title":"Annu Rev Med"},{"key":"202_CR53","doi-asserted-by":"publisher","first-page":"940674","DOI":"10.3389\/fimmu.2022.940674","volume":"13","author":"R Salomon","year":"2022","unstructured":"Salomon R, Dahan R. Next generation CD40 agonistic antibodies for cancer immunotherapy. Front Immunol. 2022;13:940674.\u00a0https:\/\/doi.org\/10.3389\/fimmu.2022.940674.","journal-title":"Front Immunol"},{"issue":"1","key":"202_CR54","doi-asserted-by":"publisher","first-page":"e003809","DOI":"10.1136\/jitc-2021-003809","volume":"10","author":"R Wang","year":"2022","unstructured":"Wang R, Chen J, Wang W, Zhao Z, Wang H, Liu S, et al. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model. J Immunother Cancer. 2022;10(1):e003809.\u00a0https:\/\/doi.org\/10.1136\/jitc-2021-003809.","journal-title":"J Immunother Cancer."},{"issue":"5\u20136","key":"202_CR55","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1089\/hum.2021.197","volume":"33","author":"SC Lu","year":"2022","unstructured":"Lu SC, Hansen MJ, Hemsath JR, Parrett BJ, Zell BN, Barry MA. Modulating oncolytic adenovirus immunotherapy by driving two axes of the immune system by expressing 4\u20131BBL and CD40L. Human gene therapy. 2022;33(5\u20136):250\u201361. https:\/\/doi.org\/10.1089\/hum.2021.197.","journal-title":"Human gene therapy."},{"key":"202_CR56","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.omto.2021.02.006","volume":"20","author":"E Ylosmaki","year":"2021","unstructured":"Ylosmaki E, Ylosmaki L, Fusciello M, Martins B, Ahokas P, Cojoc H, et al. Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform. Mol Ther Oncolytics. 2021;20:459\u201369. https:\/\/doi.org\/10.1016\/j.omto.2021.02.006.","journal-title":"Mol Ther Oncolytics"},{"issue":"10\u201311","key":"202_CR57","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1038\/s41417-020-00271-8","volume":"28","author":"S Irenaeus","year":"2021","unstructured":"Irenaeus S, Hellstrom V, Wenthe J, Krause J, Sundin A, Ahlstrom H, et al. Intratumoral immunostimulatory AdCD40L gene therapy in patients with advanced solid tumors. Cancer Gene Ther. 2021;28(10\u201311):1188\u201397. https:\/\/doi.org\/10.1038\/s41417-020-00271-8.","journal-title":"Cancer Gene Ther"},{"issue":"3\u20134","key":"202_CR58","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1089\/hum.2020.222","volume":"32","author":"S Zafar","year":"2021","unstructured":"Zafar S, Basnet S, Launonen IM, Quixabeira DCA, Santos J, Hemminki O, et al. Oncolytic adenovirus type 3 coding for CD40L facilitates dendritic cell therapy of prostate cancer in humanized mice and patient samples. Hum Gene Ther. 2021;32(3\u20134):192\u2013202. https:\/\/doi.org\/10.1089\/hum.2020.222.","journal-title":"Hum Gene Ther"},{"issue":"9","key":"202_CR59","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.7150\/jca.71992","volume":"13","author":"M Garofalo","year":"2022","unstructured":"Garofalo M, Pancer KW, Wieczorek M, Staniszewska M, Salmaso S, Caliceti P, et al. From immunosuppression to immunomodulation - turning cold tumours into hot. J Cancer. 2022;13(9):2884\u201392. https:\/\/doi.org\/10.7150\/jca.71992.","journal-title":"J Cancer"},{"issue":"18","key":"202_CR60","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.2217\/nnm-2020-0156","volume":"15","author":"A Saraswat","year":"2020","unstructured":"Saraswat A, Patki M, Fu Y, Barot S, Dukhande VV, Patel K. Nanoformulation of PROteolysis TArgeting chimera targeting \u2018undruggable\u2019 c-Myc for the treatment of pancreatic cancer. Nanomedicine (Lond). 2020;15(18):1761\u201377. https:\/\/doi.org\/10.2217\/nnm-2020-0156.","journal-title":"Nanomedicine (Lond)"},{"issue":"1","key":"202_CR61","doi-asserted-by":"publisher","first-page":"e08702","DOI":"10.1016\/j.heliyon.2021.e08702","volume":"8","author":"A Saraswat","year":"2022","unstructured":"Saraswat A, Vemana HP, Dukhande VV, Patel K. Galactose-decorated liver tumor-specific nanoliposomes incorporating selective BRD4-targeted PROTAC for hepatocellular carcinoma therapy. Heliyon. 2022;8(1):e08702.\u00a0https:\/\/doi.org\/10.1016\/j.heliyon.2021.e08702.","journal-title":"Heliyon"},{"issue":"1","key":"202_CR62","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s43556-023-00126-2","volume":"4","author":"Z Xie","year":"2023","unstructured":"Xie Z, Zhou Z, Yang S, Zhang S, Shao B. Epigenetic regulation and therapeutic targets in the tumor microenvironment. Mol Biomed. 2023;4(1):17. https:\/\/doi.org\/10.1186\/s43556-023-00126-2.","journal-title":"Mol Biomed"},{"issue":"1","key":"202_CR63","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s43556-022-00099-8","volume":"3","author":"R Xia","year":"2022","unstructured":"Xia R, Xu M, Yang J, Ma X. The role of hedgehog and notch signaling pathway in cancer. Mol Biomed. 2022;3(1):44. https:\/\/doi.org\/10.1186\/s43556-022-00099-8.","journal-title":"Mol Biomed"},{"issue":"1","key":"202_CR64","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s43556-023-00147-x","volume":"4","author":"H Zhang","year":"2023","unstructured":"Zhang H, Liu X, Zhang W, Deng J, Lin C, Qi Z, et al. Oncogene SCARNA12 as a potential diagnostic biomarker for colorectal cancer. Mol Biomed. 2023;4(1):37. https:\/\/doi.org\/10.1186\/s43556-023-00147-x.","journal-title":"Mol Biomed"},{"issue":"1","key":"202_CR65","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s43556-022-00086-z","volume":"3","author":"Y Hao","year":"2022","unstructured":"Hao Y, Chung CK, Gu Z, Schomann T, Dong X, Veld RVHI, et al. Combinatorial therapeutic approaches of photodynamic therapy and immune checkpoint blockade for colon cancer treatment. Mol Biomed. 2022;3(1):26. https:\/\/doi.org\/10.1186\/s43556-022-00086-z.","journal-title":"Mol Biomed"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-024-00202-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-024-00202-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-024-00202-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,22]],"date-time":"2024-09-22T03:17:15Z","timestamp":1726975035000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-024-00202-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,22]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["202"],"URL":"https:\/\/doi.org\/10.1186\/s43556-024-00202-1","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,22]]},"assertion":[{"value":"22 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures of animal experiments were approved by the Committee on Animal Care and Use and the Committee on the Ethics of Animal Experiments of Ningbo University (APPROVAL NUMBER: 2020\u2009\u2212\u2009118).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39"}}